Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells

Vinata B. Lokeshwar, Luis E. Lopez, Daniel Munoz, Andrew Chi, Samir P. Shirodkar, Soum D. Lokeshwar, Diogo O. Escudero, Neetika Dhir, Norman Altman

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

4-Methylumbelliferone (4-MU) is a hyaluronic acid (HA) synthesis inhibitor with anticancer properties; the mechanism of its anticancer effects is unknown. We evaluated the effects of 4-MU on prostate cancer cells. 4-MU inhibited proliferation, motility, and invasion of DU145, PC3-ML, LNCaP, C4-2B, and/or LAPC-4 cells. At IC50 for HA synthesis (0.4 mmol/L), 4-MU induced >3-fold apoptosis in prostate cancer cells, which could be prevented by the addition of HA. 4-MU induced caspase-8, caspase-9, and caspase-3 activation, PARP cleavage, upregulation of Fas-L, Fas, FADD and DR4, and downregulation of bcl-2, phosphorylated bad, bcl-XL, phosphorylated Akt, phosphorylated 1KB, phosphorylated ErbB2, and phosphorylated epidermal growth factor receptor. At ICS0, 4-MU also caused >90% inhibition of NF-KB reporter activity, which was prevented partially by the addition of HA. With the exception of caveolin-1, HA reversed the 4-MU-induced downregulation of HA receptors (CD44 and RHAMM), matrix-degrading enzymes (MMP-2 and MMP-9), interleukin-8, and chemokine receptors (CXCRl, CXCR4, and CXCR7) at the protein and mRNA levels. Expression of myristoylated-Akt rescued 4-MU-induced apoptosis and inhibition of cell growth and interleukin-8, RHAMM, HAS2, CD44, and MMP-9 expression. Oral administration of 4-MU significantly decreased PC3-ML tumor growth (>3-fold) when treatment was started either on the day of tumor cell injection or after the tumors became palpable, without organ toxicity, changes in serum chemistry, or body weight. Tumors from 4-MU-treated animals showed reduced microvessel density (~3-fold) and HA expression but increased terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells and expression of apoptosisrelated molecules. Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling.

Original languageEnglish (US)
Pages (from-to)2613-2623
Number of pages11
JournalCancer Research
Volume70
Issue number7
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Hymecromone
Hyaluronic Acid
Prostatic Neoplasms
Matrix Metalloproteinases
Neoplasms
Down-Regulation
Interleukin-8 Receptors
Apoptosis
Caveolin 1
DNA Nucleotidylexotransferase
Caspase 9
Caspase 8
Chemokine Receptors
Growth
Microvessels
Interleukin-8
Epidermal Growth Factor Receptor
Caspase 3
Inhibitory Concentration 50
Oral Administration

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. / Lokeshwar, Vinata B.; Lopez, Luis E.; Munoz, Daniel; Chi, Andrew; Shirodkar, Samir P.; Lokeshwar, Soum D.; Escudero, Diogo O.; Dhir, Neetika; Altman, Norman.

In: Cancer Research, Vol. 70, No. 7, 01.04.2010, p. 2613-2623.

Research output: Contribution to journalArticle

Lokeshwar, VB, Lopez, LE, Munoz, D, Chi, A, Shirodkar, SP, Lokeshwar, SD, Escudero, DO, Dhir, N & Altman, N 2010, 'Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells', Cancer Research, vol. 70, no. 7, pp. 2613-2623. https://doi.org/10.1158/0008-5472.CAN-09-3185
Lokeshwar, Vinata B. ; Lopez, Luis E. ; Munoz, Daniel ; Chi, Andrew ; Shirodkar, Samir P. ; Lokeshwar, Soum D. ; Escudero, Diogo O. ; Dhir, Neetika ; Altman, Norman. / Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. In: Cancer Research. 2010 ; Vol. 70, No. 7. pp. 2613-2623.
@article{c95022cb48bb4bf693ae0a5bb4723a79,
title = "Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells",
abstract = "4-Methylumbelliferone (4-MU) is a hyaluronic acid (HA) synthesis inhibitor with anticancer properties; the mechanism of its anticancer effects is unknown. We evaluated the effects of 4-MU on prostate cancer cells. 4-MU inhibited proliferation, motility, and invasion of DU145, PC3-ML, LNCaP, C4-2B, and/or LAPC-4 cells. At IC50 for HA synthesis (0.4 mmol/L), 4-MU induced >3-fold apoptosis in prostate cancer cells, which could be prevented by the addition of HA. 4-MU induced caspase-8, caspase-9, and caspase-3 activation, PARP cleavage, upregulation of Fas-L, Fas, FADD and DR4, and downregulation of bcl-2, phosphorylated bad, bcl-XL, phosphorylated Akt, phosphorylated 1KB, phosphorylated ErbB2, and phosphorylated epidermal growth factor receptor. At ICS0, 4-MU also caused >90{\%} inhibition of NF-KB reporter activity, which was prevented partially by the addition of HA. With the exception of caveolin-1, HA reversed the 4-MU-induced downregulation of HA receptors (CD44 and RHAMM), matrix-degrading enzymes (MMP-2 and MMP-9), interleukin-8, and chemokine receptors (CXCRl, CXCR4, and CXCR7) at the protein and mRNA levels. Expression of myristoylated-Akt rescued 4-MU-induced apoptosis and inhibition of cell growth and interleukin-8, RHAMM, HAS2, CD44, and MMP-9 expression. Oral administration of 4-MU significantly decreased PC3-ML tumor growth (>3-fold) when treatment was started either on the day of tumor cell injection or after the tumors became palpable, without organ toxicity, changes in serum chemistry, or body weight. Tumors from 4-MU-treated animals showed reduced microvessel density (~3-fold) and HA expression but increased terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells and expression of apoptosisrelated molecules. Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling.",
author = "Lokeshwar, {Vinata B.} and Lopez, {Luis E.} and Daniel Munoz and Andrew Chi and Shirodkar, {Samir P.} and Lokeshwar, {Soum D.} and Escudero, {Diogo O.} and Neetika Dhir and Norman Altman",
year = "2010",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-09-3185",
language = "English (US)",
volume = "70",
pages = "2613--2623",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells

AU - Lokeshwar, Vinata B.

AU - Lopez, Luis E.

AU - Munoz, Daniel

AU - Chi, Andrew

AU - Shirodkar, Samir P.

AU - Lokeshwar, Soum D.

AU - Escudero, Diogo O.

AU - Dhir, Neetika

AU - Altman, Norman

PY - 2010/4/1

Y1 - 2010/4/1

N2 - 4-Methylumbelliferone (4-MU) is a hyaluronic acid (HA) synthesis inhibitor with anticancer properties; the mechanism of its anticancer effects is unknown. We evaluated the effects of 4-MU on prostate cancer cells. 4-MU inhibited proliferation, motility, and invasion of DU145, PC3-ML, LNCaP, C4-2B, and/or LAPC-4 cells. At IC50 for HA synthesis (0.4 mmol/L), 4-MU induced >3-fold apoptosis in prostate cancer cells, which could be prevented by the addition of HA. 4-MU induced caspase-8, caspase-9, and caspase-3 activation, PARP cleavage, upregulation of Fas-L, Fas, FADD and DR4, and downregulation of bcl-2, phosphorylated bad, bcl-XL, phosphorylated Akt, phosphorylated 1KB, phosphorylated ErbB2, and phosphorylated epidermal growth factor receptor. At ICS0, 4-MU also caused >90% inhibition of NF-KB reporter activity, which was prevented partially by the addition of HA. With the exception of caveolin-1, HA reversed the 4-MU-induced downregulation of HA receptors (CD44 and RHAMM), matrix-degrading enzymes (MMP-2 and MMP-9), interleukin-8, and chemokine receptors (CXCRl, CXCR4, and CXCR7) at the protein and mRNA levels. Expression of myristoylated-Akt rescued 4-MU-induced apoptosis and inhibition of cell growth and interleukin-8, RHAMM, HAS2, CD44, and MMP-9 expression. Oral administration of 4-MU significantly decreased PC3-ML tumor growth (>3-fold) when treatment was started either on the day of tumor cell injection or after the tumors became palpable, without organ toxicity, changes in serum chemistry, or body weight. Tumors from 4-MU-treated animals showed reduced microvessel density (~3-fold) and HA expression but increased terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells and expression of apoptosisrelated molecules. Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling.

AB - 4-Methylumbelliferone (4-MU) is a hyaluronic acid (HA) synthesis inhibitor with anticancer properties; the mechanism of its anticancer effects is unknown. We evaluated the effects of 4-MU on prostate cancer cells. 4-MU inhibited proliferation, motility, and invasion of DU145, PC3-ML, LNCaP, C4-2B, and/or LAPC-4 cells. At IC50 for HA synthesis (0.4 mmol/L), 4-MU induced >3-fold apoptosis in prostate cancer cells, which could be prevented by the addition of HA. 4-MU induced caspase-8, caspase-9, and caspase-3 activation, PARP cleavage, upregulation of Fas-L, Fas, FADD and DR4, and downregulation of bcl-2, phosphorylated bad, bcl-XL, phosphorylated Akt, phosphorylated 1KB, phosphorylated ErbB2, and phosphorylated epidermal growth factor receptor. At ICS0, 4-MU also caused >90% inhibition of NF-KB reporter activity, which was prevented partially by the addition of HA. With the exception of caveolin-1, HA reversed the 4-MU-induced downregulation of HA receptors (CD44 and RHAMM), matrix-degrading enzymes (MMP-2 and MMP-9), interleukin-8, and chemokine receptors (CXCRl, CXCR4, and CXCR7) at the protein and mRNA levels. Expression of myristoylated-Akt rescued 4-MU-induced apoptosis and inhibition of cell growth and interleukin-8, RHAMM, HAS2, CD44, and MMP-9 expression. Oral administration of 4-MU significantly decreased PC3-ML tumor growth (>3-fold) when treatment was started either on the day of tumor cell injection or after the tumors became palpable, without organ toxicity, changes in serum chemistry, or body weight. Tumors from 4-MU-treated animals showed reduced microvessel density (~3-fold) and HA expression but increased terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive cells and expression of apoptosisrelated molecules. Therefore, the anticancer effects of 4-MU, an orally bioavailable and relatively nontoxic agent, are primarily mediated by inhibition of HA signaling.

UR - http://www.scopus.com/inward/record.url?scp=77950845327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950845327&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-3185

DO - 10.1158/0008-5472.CAN-09-3185

M3 - Article

C2 - 20332231

AN - SCOPUS:77950845327

VL - 70

SP - 2613

EP - 2623

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -